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Abstract As a result of mandatory labelling legislation, major food allergens that commonly
cause allergic reactions are declared on packaging. The usage of precautionary allergen
labelling (PAL) on packaging is not regulated in all countries, and the food industry uses
various forms of “may contain” labelling which firstly is often inconsistent and secondly over
time may diminish the value of such advisory statements. Hence, the aims of this paper are to
review the current industry usage of PAL and to provide recommendations on future use that
are of value to academics, policy makers, food industry, and consumers. A case study example
is used to illustrate the likely costs and benefits of improving the current PAL status by
considering a “peanut-free” product and calculation using the Voluntary Incidental Trace
Allergen Labelling (VITAL) calculator. Governance such as addressing the inconsistent usage
of PALs, promoting the harmonization of language used in PALs, and improving PAL status to
quantified PAL statements would be helpful in communicating risks to consumers, so they can
make informed choices when purchasing food products.
Keywords Allergens . Eliciting dose . Precautionary allergen labelling (PAL) . Quantified PAL
Introduction
Food allergy, as a condition, results in an adverse immune response to proteins in foods that
can be immunoglobulin E (IgE)-mediated, non-IgE-mediated, or a combination of both (Kulis
et al. 2015; Sicherer and Sampson 2010). The immune response can trigger a number of
symptoms involving the skin, digestive, respiratory, and cardiovascular systems (Boyce et al.
2010). Some of the most common food allergens are highly prevalent in the USA such as fish,
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eggs, milk, peanuts, shellfish, soy, tree nuts, and wheat (Boyce et al. 2010; Branum and Lukacs
2009), whilst sesame (Dano et al. 2015), lupine (Jappe and Vieths 2010), mustard (Sirvent
et al. 2012), and celery (Fuchs et al. 2012) have been identified as major allergenic food
sources in European countries. Shellfish is the most common food allergen from Asia (Lee
et al. 2013; Shek et al. 2010; Wu et al. 2012) whilst egg and cow’s milk allergies are most
prevalent among young children and infants in Asia too (Chen et al. 2011; Lee et al. 2013; Wu
et al. 2012). Estimates for the total number of consumers affected by food allergies range from
1–2% adults and 5–8% children in westernized countries (Gupta et al. 2011; Patel et al. 2011;
Tang and Hsiao 2016). The above studies are examples of common allergens occurring in
specific countries as a result of geographic and dietary variations.
As there is no preventive medical treatment for food allergies and in extreme cases
such allergies can result in symptoms such as anaphylactic shock, in order to avoid
allergic reactions, strict avoidance of the allergenic food is the only mechanism available
to sensitive individuals (Burks et al. 2012). In order to protect consumers, regulations are
in place across the world, e.g., the Food Allergen Labelling and Consumer Protection
Act of 2004 (US FDA 2016), EU Regulation No. 1169/ (2011), GB 7718-2011 The
General Rules for the Labelling of Prepackaged Food (CIRS 2014; USDA Gain Report
2011), and Standard 1.2.3—Mandatory Warning and Advisory Statements and Declara-
tions (FSANZ 2014). These regulations state that the foods that cause the most common
allergenic reactions need to have their presence identified on food product labels, where
the description of the product alone will not give an indication, e.g., milk labelled as
milk, nuts labelled as nuts (Table 1).
In EU Regulation No. 1169/2011, 14 food allergens are listed as requiring mandatory
labelling. However, legislation does not consider the wider need for warnings with
regard to traces of allergenic material that at some point in the food supply chain may
cross-contaminate and form an inclusion in what otherwise is considered in the legisla-
tion context as a non-allergenic food product. This argument was first highlighted more
than a decade ago by Anandan and Sheikh (2005) and Said and Weiner (2004) leading to
food manufacturers using an “alibi” or precautionary allergen labelling (PAL) on their
packaging via statements such as “may contain” where there is a potential for cross-
contamination (Luber et al. 2015). The aim of this paper is to review the development
and use of PAL, then consider the proliferation of various types of PAL descriptors. This
in turn will provide recommendations for the development of a quantified PAL approach
based on threshold doses and risk assessment and management that then act as a guide
for the food industry and practitioners in assessing the need to provide “may contain”
labelling. The structure of the paper will firstly examine the literature and then build on
this through reviewing the role of PAL in preventing accidental exposure to allergens and
the techniques to undertake quantitative mechanisms of risk assessment in order to
inform the use of PAL followed by an estimation using cost–benefit analysis. A case
study example is used to illustrate the cost and the benefit where a quantified PAL
approach is conducted.
Food Allergen Labelling Regulations
There is an innate degree of uncertainty with regard to the actual risk of allergenic cross-
contamination and lack of information on the threshold levels above which allergenic
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reactions in sensitive individuals are triggered (Ford et al. 2010). This has prompted the
food manufacturing sector to introduce PAL (Allen et al. 2014). Voluntary PAL is often
undertaken by the food industry to warn of the potential for cross-contamination (and
cross-contact) such as in the instance of shared manufacturing equipment and/or facili-
ties. In a number of countries, this approach is not formalized and the prevalence of
multiple types of PAL statements remains high (Zurzolo et al. 2012) which is potentially
unhelpful to consumers (Turner et al. 2016). Indeed, it has been suggested that the use of
PAL is an intentional strategy to mitigate multiple levels of risk (on the spectrum from
low to high) and thus is used to cover the manufacturers’ back and/or to protect supply
chain actors against product liability claims (Pape 2009).
Based on the UK “FreeFrom” survey conducted among FreeFrom’s 5000 newsletter
subscribers, 45% of consumers were totally confused about the “may contain” labelling;
a further 36% believed that the product would actually contain the allergens in the
warning, whilst 19% did not pay attention to the labelling at all (Berriedale-Johnson
2015). There are currently four scenarios of using PAL:
& Scenario 1: PAL-labelled food products that have a genuine risk of causing allergic
reactions
& Scenario 2: Products where there is no serious allergenic risk involved, but manufacturers
may feel obliged to ensure that labels carry the warning to cover even the potential of a
minor risk
& Scenario 3: Products that would not carry PAL because there is no risk of allergenic
contamination, but there is concern that consumers would be confused when they cannot
find PAL on a product, so as a result, it is included
& Scenario 4: Products where manufacturers are actually unaware of the actual need for PAL
Therefore, initiatives that can make PAL more meaningful will be valuable to all actors in
the supply chain, especially manufacturers and consumers. In order to provide an overview of
the economic details and cost–benefit of quantified PAL, this study utilizes a theoretical
example of a food product manufactured on a production site that also uses other food
allergens (Manning and Soon 2016). The worked example includes the estimated price of
the genuine food product in a small–medium company and the cost of purchasing allergen test
kits. The actual and approximate costs of raw materials and test kits were considered.
Legislation often considers the use of PAL to be an adequate and appropriate safety
measure (Pape 2009). In the UK, advisory labelling takes the form of “may contain (an
allergen),” “made on equipment that also processes (an allergen),” or “made in a factory
that also handles (an allergen)” to warn consumers of potential cross-contamination risks
(FSA 2015). Labelling rules contained within the European Directives 2003/89/EC and
2006/142/EC required comprehensive ingredient listing information. This regulation was
built upon by the implementation of the Food Information for Consumers Regulation
(FIR) (EU) No. 1169/2011 that became legislation in the UK in December 2014. Article
36 in the EU Regulation No. 1169/2011 covers the general requirements that voluntary
food information must meet the following:
& It shall not mislead the consumer.
& It shall not be ambiguous or confusing for the consumer.
& It shall, where appropriate, be based on relevant scientific data.
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According to Article 36.3a of the FIR legislation, the European Commission shall adopt the
above measures when implementing voluntary “may contain” labelling, i.e., information on
the possible and unintentional presence in food of substances or products causing allergies or
intolerances (EU Regulation No. 1169/2011 2011). Similarly, the US Food and Drug Admin-
istration (FDA 2006) and Health Canada (2012) advise that PAL must be truthful, not
misleading, non-ambiguous, and not to be used as a substitute for implementing operational
prerequisite programmes such as Good Manufacturing Practices (GMPs). Japan does not allow
“may contain” labelling and reported that if such labelling was recognized at the regulatory
level, then some manufacturers may choose to escape liability as provided in the Product
Liability Act (Ministry of Health, Labour and Welfare n.d.). International legislative require-
ments for PAL have been synthesized as part of this research (Table 2), and examples of
common PAL statements that are found on labels are collated (Table 3).
Based on Table 2, it is noted that Japan, Switzerland, and South Africa also regulate “may
contain” labelling. In Switzerland, only ingredients that have not been added voluntarily and
exceeded 10 mg/100 g gluten in cereals or 1 g/kg or litre for other allergens must be declared
(Federal Department Affairs 2005). PAL labelling is prohibited in Argentina (Argentina Food
Code 2010) whilst South Africa requires documented risk assessment and steps taken to avoid
allergen cross-contamination (Department of Health, Government of South Africa 2010).
Although there is limited evidence on why certain countries have chosen to regulate or not
to regulate PAL, different countries do have different allergen and precautionary labelling
requirements due to the variable prevalence of such allergens and also different dietary
preferences (Hattersley and Ward 2014). Japan is a notable exception. In Japan, 10 μg
protein/g food is used as the threshold to monitor the labelling. This level is considered as
the minimum for controlling the contamination of allergic ingredients using a detection
method (e.g., enzyme-linked immunosorbent assay [ELISA]) for routine and industrial anal-
yses (Akiyama et al. 2011). The authors hope that the case study example in the latter section
of this paper will not only provide food manufacturers and consumers with a better under-
standing of the PAL system but also underline for regulators the option to adopt risk-based
approaches in PAL.
Role of PAL in Accidental Exposures to Allergens
Consumers assume that a product does not contain an allergen if an allergy advice box is
absent from the labelling (Barnett et al. 2011a). Gluten-free (GF)-labelled foods, with state-
ments such as “produced in a facility that also processes wheat” or “made on equipment shared
with wheat,” also confuse consumers (Sharma et al. 2015). Up to 90% of food products
bearing peanut advisory statements did not contain any protein that can cause an allergic
reaction (Hefle et al. 2007). Ong (2008) argued that this use of PAL can frustrate and restrict
consumers’ food choice and may lead to health issues due to nutrient imbalance. Further, at
times, allergenic individuals may choose to ignore PAL and take risks with food products
bearing PAL statements. Hefle et al. (2007) reported that consumers were more likely to heed
PAL in 2003 (85%) compared to 2006 (75%). It could be asserted that the proliferation of PAL
statements across multiple food items could have resulted in “label fatigue” among consumers
and may increase the tendency for people to disregard advisory labelling (Robertson et al.
2013) or revert to unhealthy choices (Thorndike et al. 2014). Studies found that in the sample
group, 6.3% (Sheth et al. 2008) and 8.3% (n = 695) (Sheth et al. 2010) of allergic individuals
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Table 3 Precautionary allergen labelling (PAL) with examples of different wording used
PAL with different wordings Examples of advisory labelling of prepacked processed foods
May contain, contains,
free-related labelling
May contain traces of wheat and barley due to farming practices
Contains: milk, wheat, gluten. This product contains no nuts.
However, we cannot guarantee the ingredients used are nut-free
Contains wheat, gluten. Manufactured in a nut-free environment.
Nut-free, dairy-free, gluten-free, egg-free
Contains milk. Dietary advice: suitable for vegetarians. Gluten-free
Contains milk, soy. Recipe contains cashew nuts. May contain
traces of other nuts
Production, packaging, factory,
premises, manufacturing
method-related advisory
labelling
Made in premises which produce nut products
Contains wheat, milk. Produced on a line handling soy and in a
factory handling egg, hazelnut but on a different line
Packed on a production line that also packs nuts, seed, and cereals
that contain gluten. Therefore cannot be guaranteed nut-, seed- or
gluten-free
Contains milk, wheat, gluten, soy. Recipe: No nuts. Ingredients:
Cannot guarantee nut-free. Factory: Product made in nut-free area,
but nuts used elsewhere
Contains eggs, wheat, oats, gluten. Not suitable for cow’s milk and
sesame allergy sufferers due to manufacturing methods used
Contains soy, milk. May contain nuts, cereals. This product contains
milk due to the unavoidable cross-contamination from milk
chocolate made on the same manufacturing line.
Contains: milk. Recipe: No nuts. Ingredients: Cannot guarantee
nut-free. Factory: Before being prepared for manufacture of this
product, the equipment was previously used to make products
containing nuts. Product may contain traces of soy.
Contains milk and soy products. May contain traces of hazelnuts,
almonds, and peanuts due to shared equipment.
Contains milk and soy. Not suitable for nut or wheat gluten allergy
sufferers due to manufacturing methods.
This recipe contains gluten, egg, fish, and milk. We made it in a
busy working kitchen so it may also contain traces of nuts and
sesame.
Food fact: This product may contain traces of nuts and seeds.
Allergen advice: Contains egg, gluten, milk, and soy. Manufactured
on a site that also handles celery, fish, molluscs, mustard, nuts,
peanuts, and sulphites.
Contains wheat, gluten, and barley. Produced in a factory which
handles milk powder. Not suitable for people with nut allergy.
This product is manufactured in a factory which uses sesame seeds,
lentils, wheat, and nuts. Therefore, this product may contain
trace allergens. This product contains peanuts.
Our packing house handles nuts and seeds
May contain traces of soy. Manufactured under controlled conditions
in our own factory in which no nuts are ever used.
Contains dairy. May contain nut traces. Vegetarian. Free from gluten,
soy, GM, colouring, and preservatives. Made in a factory where
peanuts and sesame seeds are used.
Allergy advice: Contains eggs and milk. Produced in a factory that
handles wheat, gluten, soy, nuts (cashew), sesame, and mustard.
Mycoprotein is high in protein and fibre. This may cause
intolerance in some people.
Other advisory labelling Any allergies? I contain celery. I have been known to hang around
near nuts, peanuts, and sesame seeds and I may contain them as well.
Do not munch if you are allergic to soy beans and sesame seeds.
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who ignored PAL went on to have a resultant allergic reaction to the material that was present
in the product through cross-contamination. Further, the variations in precautionary labels used
to inform consumers of the scenarios faced within manufacturing and the necessary steps taken
to minimize risk mean that the wording can be perceived and possibly graded by consumers as
identifying different levels of risk, and this influences buying decisions (Verrill and Choinière
2009). This suggests that customers will, individually or on behalf of others, apply a quanti-
tative assessment to what is a qualitative statement and on that basis exhibit risk-taking
behaviour. The main function of PAL is to warn allergic individuals of the potential risk if
they were to consume a given product. However, PAL acts like a double-edged sword as on the
one hand, it is trying to protect consumers but on the other, consumers can choose either to
ignore the warning due to label fatigue or to bypass all foods of that type because of historic
allergic reactions to foods after consuming PAL products in the past. The use of perception or
inference by consumers is a reductionist way of navigating a given set of often complex issues
or challenges. This is often because consumers lack access to, or the understanding to interpret,
complex statistics (Slovic et al. 1981), so instead, they use cues from past experience or
observation in their decision-making. A heuristic can be described as an approach, or
technique, that is used by individuals to solve problems, make judgements, and form decisions.
Thus, in order to consider, deliberate, and come to a decision on a given problem, a decision-
making approach can be used by consumers when they apply an assessment to what is often
just a qualitative statement by manufacturers and on that basis exhibit what would be seen by
some as risk-taking behaviour.
The challenge is further nuanced by the fact that in some countries, legislation is
approached in terms of product liability, e.g., in the USA and Canada, when in others, such
as in Europe, the precautionary principle informs the application of the regulation. Although in
Europe, in order to actually demonstrate adherence to GMPs, the food industry needs to
implement appropriate monitoring and verification activities, so the food industry is required
to exercise reasonable precautions and demonstrate due diligence. It is within that context that
the use of PAL should be substantiated by a documented formal risk assessment. Whilst
qualitative approaches to monitoring and verification may include observation and assessment
of work practices for compliance with the formalized documented allergen control systems, a
quantitative approach would test the intrinsic nature of the product produced and whether a
protein capable of producing an allergenic reaction in individuals that are sensitive is actually
present. Thus, whether through market drivers such as either shareholder requirements for
Table 3 (continued)
PAL with different wordings Examples of advisory labelling of prepacked processed foods
Contains nuts and peanuts. In our bakery, we use soy, cow’s milk,
and sesame seeds. We cannot be absolutely sure they will not
find their way into this bar.
Some chocolates contain nuts and soya, but all chocolates contain
milk and traces of nuts and soya.
Contains: hazelnuts, almonds, milk, soy. May contain: other nuts.
Some chocolates contain nuts. All chocolates may contain parts
of or traces of nuts.
Allergy advice: See list of ingredients
Adapted from FSA 2014
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business managers to mitigate the potential risk associated with their dividend payments, as an
ethical or moral requirement to provide safe food for all consumers, or as a regulatory need to
provide safe food, managers are required to take up more responsibility to accurately measure
the amount of allergenic material in their products. Bearing in mind not only the existence of
numerous small and medium food companies that operate in a wider supply chain or network
controlled by multinational corporations (MNCs) but also the cost of quantitatively detecting
and measuring proteinaceous material that can cause an allergenic reaction in some individ-
uals, this quantitative approach to risk mitigation would have serious financial implications for
these small companies if the need for improved allergen control became a prerequisite to
supply. This is explored in further detail in the cost–benefit analysis of a chia seed and raisin
bar product later in this paper.
It is noted in the literature that consumers with a recognized food allergy are more likely to
purchase products with “shared facilities” than “shared equipment” labelling (Hefle et al.
2007). However, when considering “shared equipment” and “may contain” labelling, con-
sumers were more likely to purchase from the former label (Hefle et al. 2007). Consumers
most commonly avoid “not suitable for [allergen] allergy sufferers” followed by “may contain”
labelling (Sheth et al. 2008) (Fig. 1). Ong (2008) also reported that susceptible consumers are
not only prevented from consuming food that declare allergens but also have to avoid food
products with such advisory labelling. Based on previous experience, consumers use their own
strategies, i.e., heuristics in dealing with PAL products (Barnett et al. 2011b). Peters et al.
(2004) argue that whilst in a business setting, risk and benefit are often positively correlated,
i.e., the greater the risk the greater the return, conversely, they are negatively correlated in the
minds of the public, suggesting that an affect heuristic plays a role in risk assessment, i.e., a
combination of what people think and what they feel rather than analytical decision-making.
The severity of subsequent allergenic reactions cannot be predicted from symptoms
reported during initial reactions (Crevel et al. 2014; Pumphrey 2004; Vander Leek et al.
2000). Extrinsic factors such as medical and drug history or exercise may enhance the
absorption of allergenic protein. Thus, with the current system of PAL, the extrapolation or
creation of personal risk hierarchies by consumers from assessing qualitative statements and
converting them to risk-based decisions is flawed (Fig. 1). As part of this work, a review of
relevant literature around the detection of allergens in PAL-designated products shows that in
many studies, the actual proportion of products that contained the allergen was low, but for
some sensitive individuals, these products still present a clear risk (Table 4).
FreeFrom proposed an independent, validated certification known as “Allergen Safe” for
manufacturers whose allergen controls and management meet FSA guidelines (Berriedale-
Johnson 2015). Allergen Safe strives to create awareness among allergic consumers or
customers who opt for a free-from diet so they can purchase with confidence, reduce their
risk of allergic reactions to food, and increase their food choices. Manufacturers also have the
added benefit of new business in the “free-from” sector and also a decrease in fear of
prosecution. However, manufacturers must be able to demonstrate that this approach
contains an effective validation step and then ongoing process and product verification to
ensure that standards are maintained. Remington et al. (2013) proposed the use of a probabi-
listic risk assessment tool to determine if the usage of advisory labelling is actually appropriate.
As consumers are paying lesser attention to advisory labels, due often to the proliferation of
PALs and based on consumers’ prior experiences (Hefle et al. 2007; Sherlock et al. 2014), a
more precise or quantified PAL would instead provide consumers with informed choices to
guide them whilst purchasing allergen-free-labelled or PAL products. However, quantified
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Allergy information: may contain [allergen] 
/ Not suitable for [allergen] allergy sufferers 
May contain traces [allergen] / Cannot 
guarantee [allergen] free 
Packaged in a facility that also processes / 
manufactured in a facility that also 
processes; possibility of contact with 
allergenic ingredients has been minimized 
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Fig. 1 Variations of wordings and the likelihood of purchasing/consuming/serving food with precautionary
labelling that can cause a hierarchy of decision-making by consumers (Hefle et al. 2007; Noimark et al. 2009;
Sheth et al. 2008; Verrill and Choinière 2009)
Table 4 Detection of allergen in PAL food products
Products that are labelled with
advisory statements
Percentage of samples where allergens were detected
(number of positive samples/total samples)
Reference
Milk (including various milk-based
products, e.g., chocolate)
10.2 (6/59) Ford et al.
(2010)
Milk 42 (34/81) Crotty and
Taylor
(2010)
Peanuts 7.3 (13/179) Hefle et al.
(2007)
4.5 (5/112) Ford et al.
(2010)
5.3 (2/38) Robertson
et al. (2013)
8.6 (16/186) Remington
et al. (2013)
7 (5/75) FSAI (2011)
17.6 (96/544)a Pele et al.
(2007)
Eggs 1.8 (1/57) Ford et al.
(2010)
6 (1/18) FSAI (2011)
Gluten 43.4 (23/53) Sharma et al.
(2015)
Soy 3 (1/30) FSAI (2011)
Hazelnut 14.2 (75/526)b Pele et al.
(2007)
a Based on positive dipstick or positive ELISA test; percentage of positive samples excluding food products not
declaring peanut on the label
b Based on positive dipstick or positive ELISA test; percentage of positive samples excluding food products not
declaring hazelnut on the label
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PAL should be coupled with training and risk communication among manufacturers, retailers,
food services, and consumers.
Quantitative Risk Assessment to Predict Allergenic Reactions
Probabilistic risk assessment is one of the most promising approaches for use by risk managers
(Madsen et al. 2009) to both evaluate population at risk and also serve as a guide for PAL. This
type of assessment has been particularly useful in assessing public health threat from unde-
clared allergens in food (Spanjersberg et al. 2010). Examination of products by quantitative
testing can include using an ELISA test to detect and quantify levels of allergenic ingredients
in foods. One such approach for the examining and monitoring of allergen-labelled products is
used in Japan (Akiyama et al. 2014; Ministry of Health, Labour and Welfare n.d.). Food
containing 10 μg protein/g food or more will give a positive result using ELISA techniques. In
Japan, having established such presence using analytical tests, this is then followed up by an
investigation of manufacturing records such as raw material lists and process records. If
manufacturing records were unclear, then further confirmatory tests such as using the Western
blot method for egg and milk products or the polymerase chain reaction (PCR) method for
wheat, buckwheat, or peanut can confirm the presence of allergenic material (Akiyama et al.
2011). After thorough verification of the procedures associated with product labelling, the
allergy labelling decision tree (Fig. 2) is used to assist risk managers and the wider food
industry to confirm and make sure that the type of allergen labelling is correct. The use of
decision trees such as in Figure 2 should inform food manufacturers as to the correct labelling
for their products, i.e., whether to use mandatory, caution, recommended, prohibited, or
unnecessary labelling.
A probabilistic model can be used to predict the likelihood of an allergic reaction based on
an estimation of the proportion of allergic population, the proportion of that consuming the
food, the amount consumed, the likelihood of the food containing an allergen, and if it is
present, its actual concentration compared with the lowest observed eliciting dose (LOED) for
the given allergen (Kruizinga et al. 2008; Spanjersberg et al. 2007). By comparing the LOEDs
and the consumption of the allergen, the probability of an allergic reaction can be predicted
(Kruizinga et al. 2008; Spanjersberg et al. 2007) (Fig. 3).
The minimal eliciting dose (ED) refers to the lowest dose that can trigger an objective
reaction in a controlled clinical challenge (Luccioli and Kwegyir-Afful 2014; Taylor et al.
2010). The understanding of ED for individuals will improve consumers’ quality of life and
assist them in making more informed choices whilst purchasing food products (Luccioli and
Kwegyir-Afful 2014). Three parametric models (log logistic, log normal, and Weibull) were
applied to derive the estimates of ED1 (for peanut and cow’s milk) and both ED1 and ED5 (for
egg and hazelnut) whilst the 95% lower confidence interval of the ED5 was estimated for
soybean, wheat, sesame seed, lupine, mustard, cashew, and shrimp. See Allen et al. (2014) and
Taylor et al. (2014) for further elaboration on how the reference doses were derived. Studies
have estimated threshold doses that are derived from the ED to trigger a reaction in 1% (ED01),
5% (ED05), or 10% (ED10) of the population such as the reference doses established by the
Voluntary Incidental Trace Allergen Labelling (VITAL) expert panel group for 11 major food
allergens as listed in Table 5. Wider frustrations over PAL triggered the formation of the
Allergen Bureau of Australia and New Zealand (ABA) which later released the Labelling
VITAL programme (Fleming et al. 2010). The VITAL programme has established reference
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doses that can guide the application of precautionary labelling, ensuring that the PALs are
appropriate and relevant to the actual level of risk faced by allergic consumers. If the ingestion
of a food may result in a higher dose of allergenic food protein intake than the reference dose,
then precautionary labelling is recommended. However, the dose of the allergenic food protein
is dependent on the amount of food consumed and the concentration of the allergenic protein
(Taylor et al. 2014). The reference doses proposed by VITAL are a positive step forward for
the food industry. However, due to the variation in a given consumer’s threshold dose,
Investigate food allergy labelling  
Local government 
periodical inspection Report from consumers 
Quantitative tests (Two different ELISA kits are used) 
(Threshold 10µg/g) 
Investigation of manufacturing records 
Confirmation tests (E.g. Western blot / PCR tests) 
Correction of allergen labelling (using Ministry’s 
guide  
Depending on outcomes of ELISA, manufacturing 
records and confirmation tests, products can be 
labelled with mandatory, caution, recommended, 
prohibited or unnecessary labelling 
Fig. 2 Ministry’s guide to the inspecting and monitoring of allergy labelling system in Japan (Adapted from
Akiyama et al. 2011; Ministry of Health, Labor and Welfare n.d.)
Studies Surveys Analyses Clinical trials 
Consumption ConcentrationData 
Thresholds 
(LOEDS) Allergen intake Distribution 
Probabilistic 
model 
An allergic reaction will only occur if the amount of 
allergen present in food exceeds the minimum 
eliciting dose for the person consuming the food  
Outcome 
Fig. 3 Probabilistic approach in food allergen risk assessment (Crevel 2010; Kruizinga et al. 2008; Spanjersberg
et al. 2007)
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proposing a single reference dose remains the biggest challenge. This can be seen from the
individual studies proposing different ED values for multiple allergenic foods (Table 5). The
establishment of reference doses by public health authorities is crucial to quantifying PAL
statements.
Building on VITAL’s conception in Australia and New Zealand and similar successful
approaches in Japan and Switzerland (both Japan and Switzerland do not permit the usage of
“contain labelling”; see Table 2), the European Voluntary Incidental Trace Allergen Labelling
(EU-VITAL) was initiated at a Food Allergy meeting in 2010 to improve and harmonize the
declaration of food allergens. This approach contains three action levels that can then guide
allergen labelling in the EU (Table 6). These action levels vary by product in terms of the
threshold of allergenic substance where the action level is determined according to action level
1 (white zone where no advisory labelling is required), action level 2 (blue zone where traces
of allergen will be listed), and action level 3 (red zone where allergen will be listed as
ingredient). Future research emulating the Australian and New Zealand VITAL systems is
suggested as the levels proposed by EU-VITAL were given as concentrations (Table 6) rather
than doses (compared to Table 5). For example, allergic consumers react to doses which take
into account the concentration of the allergen in the food and the amount of food consumed.
The establishment and validation of threshold doses for major food allergens will help to
quantify precautionary labelling. Based on validated threshold doses and determination of
residues of food allergen, this will assist the food industries in developing quantitative
precautionary labelling (Allen et al. 2014). A quantified precautionary label may be helpful
for allergic consumers. In fact, the absence of a precautionary label would indicate that 95–
99% (depending on the ED) of the allergic consumers can safely ingest the food. However, it is
important that the proposed reference doses do not create unnecessary burden on most food
manufacturing industries (Crevel et al. 2014). This gives rise to some conceptual questions
such as the following: How do we balance reference doses with quantified PAL? How do we
Table 6 EU-VITAL model threshold values (mg allergenic substance/kg food [ppm] action levels (EU-VITAL
n.d.; Kuhn et al. 2010))
Action levels Labelling Declaration
1 (white zone) Not required –
2 (blue zone) Required “contains traces of [allergen]”
3 (red zone) Required as ingredient “contains [allergen] as ingredient”
Action level
1 2 3
Milk <50 50–500 >500
Egg <20 20–200 >200
Soy <25 25–250 >250
Fish <100 100–1000 >1000
Peanut <8 8–80 >80
Tree nuts <10 10–100 >100
Sesame <10 10–100 >100
Crustaceans <10 10–100 >100
Gluten <20 20–100 >100
Celery <20 20–200 >200
Lupine <20 20–200 >200
Molluscs <20 20–200 >200
Mustard <20 20–200 >200
Sulphur dioxide/sulphites <10 10–100 >100
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ensure that consumers are not further confused with the change from a “blanket approach” of
precautionary labelling to a “quantified precautionary labelling”—where, based on the refer-
ence or EDs, the quantitative guidance will help to indicate when a product should be labelled
with advise and reduce the number of foods with precautionary labelling? Figure 4 captures
some of the recommendations that can be put into practise by policy makers, e.g., via adoption
of a system similar to VITAL, risk assessors, e.g., via assessments and establishments of
reference doses nationally or regionally, food industry, e.g., via continuous due diligence, risk
assessment and management to control the risk of allergen cross-contamination at manufactur-
ing plant level, and consumers via communication through an allergen awareness group or
social media network on the benefits of quantified PAL labelling. Other strategies that can
benefit consumers and food manufacturers are to simplify “may contain” descriptors. Instead
of being creative with phrases, food manufacturers should be consistent in using PAL
wordings and this would provide a uniformity to risk communication that would benefit
consumers. A case study is now explored to consider the cost–benefit analysis of such
techniques.
Case Study: Cost–Benefit Analysis of a Food Product with Potential
Cross-Contact of Allergens
VITAL is a risk assessment tool and an online calculator that determines the level of allergens
that may be present in the food product, provides clear guidance for industries, and quantifies
PAL labelling. Users can conduct a free online trial or sign up for annual access to VITAL.
Assuming a small–medium manufacturer with 10–50 full-time equivalent employees, the
VITAL Online yearly plan costs AUS$ 990 (about US$ 750) for non-Allergen Bureau
members (Allergen Bureau 2017a). Information on recipe and raw material allergen status
and cross-contact allergens and whether these are in particulate or dispersible form should be
provided. Based on the information on allergen handling and how much could contaminate a
Fig. 4 Strategies to address
inconsistent usage of PALs
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batch, VITAL produces a “labelling outcome” about the presence of allergen due to intentional
inclusion or cross-contact (Allergen Bureau 2017b).
The following case study illustrates the example of a small–medium company (company
XYZ) that manufactures peanut, raisin, and milk chocolate confectionary bars and is planning
to manufacture chia seed and raisin bars using the same production line (Table 7). In order to
simplify the example, it has been assumed that the raisins have not been preserved with
sulphur dioxide. The milk chocolate is in a form where milk protein is not easily dissociated in
order to cause a milk-specific issue and the milk chocolate does not contain soy lecithin.
Further, as peanuts are used in the manufacturing plant for the original product, there is a risk
of cross-contamination. Peanut is selected as the allergen example here as it has the highest
prevalence among food-allergic individuals (Gupta et al. 2011) and can result in severe and
fatal reactions. Additionally, peanut as an ingredient can cause contamination as a result of
particulate contamination. The cost of manufacture per kilogram and ingredient cost per
serving (100 g) are shown (Table 7). The cost of producing the chia seed bar (500 kg) and
purchasing of peanut protein test kits is $2555.84 (i.e., $0.511/100 g). The gross cost of
determining allergen cross-contact would be $0.011 per batch.
The labelling outcomes for action levels 1 and 2 and the intentionally added allergen would
be colour coded, and guidance is provided on how to label the ingredient. For cereals
containing gluten, since this is intentionally added, this allergen is required to be declared in
the ingredient list. Milk at action level 1 represents protein from cross-contact allergen in the
final product and is not present at amounts greater than the reference dose. The cross-contact
allergen is not present at a significant amount, and a precautionary statement is not required.
Meanwhile, for peanuts which were detected in the final product and are present at an amount
≥0.2 of the reference dose, this cross-contact allergen is present in a significant amount and a
precautionary cross-contact statement for this allergen is required (Allergen Bureau 2016). The
VITAL risk assessment is an excellent guide to help food manufacturers and to provide
quantitative PAL labelling. An example of a summary of the labelling outcomes for the chia
seed and raisin bars is shown in Table 8.
Whilst reviewing Table 8, one could estimate the costs–benefits of allergen labelling
to both the manufacturers and consumers. With regard to consumers, the quantified PAL
on the chia seed and raisin bars will inform and differentiate between the potentials for
the presence of peanut. Taking into consideration that 8% of children are affected by
food allergies (Gupta et al. 2011), thus, in the USA, 6 million children, out of a total of
74 million children in 2017 (ChildStats.gov, n.d), could be affected by a change to PAL
labelling. Gupta et al. (2013) found that family members spend 27% of the indirect costs
(costs borne by family) to purchase “allergen-free” food. A more quantitative approach
to PAL would widen the food choices of consumers and provide them with informed
choices. Reduced incidence of allergic reactions would also decrease the burden on
healthcare services and the loss of productivity due to, in the case of adults affected or
adult carers of children who are affected, time taken off work. Higher medical and
indirect costs for families with food-allergic members have been noted in previous
research as a result of lost productivity and inability to carry out household and domestic
tasks (Fox et al. 2013; Voordouw et al. 2010).
The approach described in this paper is of value when compared to the use of qualitative
PAL as an allergen control measure. Allergen management protocols can be introduced as part
of a wider GMP programme, especially the use of time separation. In this approach, food
manufacturers process their products according to a given schedule, e.g., products that
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intentionally contain allergenic material are often processed as the final batch/lot of the day
prior to a full clean-down to minimize the potential for cross-contamination into subsequent
lots. Alternatively, zoning within manufacturing facilities and adoption of operational prereq-
uisite programmes are undertaken. Introducing segregation protocols within the manufacturing
environment is of value, but this can be limited if segregation protocols have not been adopted
at previous steps in the supply chain. This is why the use of PAL has become a main
preventive measure to minimize the risk of an allergenic reaction by consumers as a result
of accidental cross-contamination. Redesigning a manufacturing plant to seek to produce an
allergen-free working environment will be costly, often prohibitively so, and still, it would be
difficult to label a product as allergen-free. Taylor et al. (2002) asked the question “how clean
is clean enough?” and this can be difficult to determine and may be variable by allergen
according to the threshold dose. Manufacturers may operate a due diligence system and should
a prosecution arise, if they have carried out a thorough risk assessment and hazard analysis
critical control point (HACCP) study of potential contamination with unintended allergens,
they may have an adequate legal defence in place, but this does not necessarily protect
individual consumers that are vulnerable to a given allergen.
Conclusion
Major food allergens that commonly cause allergic reactions are usually declared on
packaging as a result of mandatory labelling legislation. This is helpful for consumers
when deciding which products to purchase. There are eight common food allergens listed
in Codex, but different regions and countries have different regulatory requirements for
allergen labelling. This is beneficial and according to local diet and geographical region
is protective of a consumer-based population. For example, royal jelly and pollens are
considered as food allergens in Australia and New Zealand, whilst buckwheat is required
to be labelled in Japan and Korea. However, the increasing global prevalence rates of
food allergies and the greater globalization of diets also call for a review of the eight
main food allergens as listed in Codex. In addition to the requirements of mandatory
labelling of intentionally added food allergens, the usage of PAL on packaging is not
regulated in all countries and where it is regulated, there is no equivalence of legislation.
As a result, the food industry uses various forms of “may contain” labelling which firstly
is often inconsistent and secondly may diminish the value of such advisory statements as
a communication tool over time.
There are four main scenarios of using PAL including genuine risk of causing allergic
reactions, potential minor risk, no risk of allergenic contamination, and unaware of the
requirements for PAL. The emergence of different types of PAL statements may add to
consumers’ frustration as well. Is there a way to harmonize or make PAL more meaningful
to both manufacturers and consumers? Can one emulate Japan, Switzerland, or South Africa in
regulating the “may contain” statement? This review calls for further research or a round-table
discussion with countries that have chosen to regulate PAL. VITAL is a beneficial programme
in Australia and New Zealand in guiding food manufacturers in ensuring the correct usage of
PALs. Similarly, Japan provides clear guidelines to inspect and monitor their local food
allergen labelling system. Susceptible consumers remain as a top priority in terms of food
safety, amidst the wider risk mitigation activities of a network of supply chain actors.
Consumers require effective risk communication and should be informed about the nature,
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content, and meaning of a given PAL statement. Strategies such as the harmonization of PALs,
addressing the inconsistent usage of PALs, and improving PAL status to give a quantified PAL
will be helpful to communicate risks to consumers so they can make informed choices when
purchasing food products. Appropriate documented risk assessment and conduction of cost–
benefit analyses of selected food products can be carried out by food manufacturers. This will
potentially widen the food choices of consumers and provide them with informed choices.
Food allergy and intolerance is not a new phenomenon, but the way it is managed is constantly
evolving especially with considerations of personalized medicine.
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